ZytoMax is now the exclusive distributor of AmoyDx® products in Switzerland
We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
AmoyDx® is a research and development-based diagnostics company with over 1000 employees that focuses on molecular diagnostics for oncological precision medicine. The primarily CE/IVD labeled qPCR and NGS products have proven to be of excellent quality and reliability, as confirmed by numerous successful external proficiency tests conducted by our customers. Furthermore, our product and laboratory team are happy to offer advice and active support during the introduction and establishment of the products.
If you are interested, please do not hesitate to contact your local contact at ZytoMax Schweiz GmbH, via e-mail at info@zytomax.ch or phone at +41 79 965 68 67.
Further topics
IVDR Update October 2022
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
PRAME (EPR20330) in dermatopathology
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]
